Simplify Asset Management Inc. Invests $11.77 Million in Sanofi (NASDAQ:SNY)

Simplify Asset Management Inc. purchased a new stake in Sanofi (NASDAQ:SNY) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 204,143 shares of the company’s stock, valued at approximately $11,765,000. Sanofi makes up 0.5% of Simplify Asset Management Inc.’s investment portfolio, making the stock its 18th largest holding.

A number of other large investors also recently bought and sold shares of the business. Barrow Hanley Mewhinney & Strauss LLC grew its holdings in Sanofi by 113.8% in the 2nd quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 5,943,547 shares of the company’s stock valued at $288,381,000 after buying an additional 3,164,092 shares in the last quarter. Magnetar Financial LLC raised its stake in shares of Sanofi by 1,153.1% in the 2nd quarter. Magnetar Financial LLC now owns 2,506,286 shares of the company’s stock valued at $121,605,000 after acquiring an additional 2,306,286 shares during the period. Bank of New York Mellon Corp boosted its position in shares of Sanofi by 19.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 8,594,740 shares of the company’s stock worth $417,017,000 after purchasing an additional 1,370,232 shares during the period. Federated Hermes Inc. lifted its stake in Sanofi by 26.5% during the second quarter. Federated Hermes Inc. now owns 3,214,141 shares of the company’s stock worth $155,950,000 after purchasing an additional 673,172 shares in the last quarter. Finally, Raymond James & Associates grew its stake in shares of Sanofi by 16.2% in the second quarter. Raymond James & Associates now owns 2,689,876 shares of the company’s stock valued at $130,513,000 after buying an additional 374,621 shares in the last quarter. Institutional investors and hedge funds own 10.04% of the company’s stock.

Analyst Ratings Changes

SNY has been the topic of a number of recent research reports. StockNews.com lowered shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 7th. Argus lifted their price objective on shares of Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a research note on Friday, July 26th. Finally, Citigroup upgraded shares of Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th. Two analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $57.50.

Sanofi Stock Up 0.3 %

Shares of SNY traded up $0.15 during trading on Friday, reaching $47.97. The company’s stock had a trading volume of 789,107 shares, compared to its average volume of 2,025,459. The company has a market cap of $121.74 billion, a price-to-earnings ratio of 24.40, a P/E/G ratio of 1.26 and a beta of 0.61. The company has a fifty day moving average of $54.85 and a two-hundred day moving average of $52.20. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17. Sanofi has a twelve month low of $45.22 and a twelve month high of $58.97.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings results on Friday, October 25th. The company reported $1.57 EPS for the quarter, beating the consensus estimate of $0.22 by $1.35. The company had revenue of $13.44 billion for the quarter, compared to analyst estimates of $16.59 billion. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. Sanofi’s revenue was up 12.3% compared to the same quarter last year. During the same quarter last year, the business earned $2.55 earnings per share. On average, sell-side analysts predict that Sanofi will post 4.27 EPS for the current fiscal year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.